Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 8, 2026, 7:35 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 361–384 of 847 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Hyperlipidaemia Clear all

Conditions: Hypertension, Hypercholesterolemia, Diabetes, Medication Adherence
Interventions: Refill synch; Behavioral
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 65 Years
Enrollment: 691 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Louisville, Kentucky

Conditions: Diabetes, Hyperlipidemia, Hypertension, Cardiovascular Disease
Interventions: CVRS Intervention; Behavioral
Lead sponsor: Korey Kennelty; Other
Eligibility: 55 Years and older
Enrollment: 402 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 18
States / cities: Gainesville, Florida • Tampa, Florida • Pocatello, Idaho + 14 more

Conditions: Peritoneal Dialysis, Hypertriglyceridemia
Interventions: Extraneal (7.5% icodextrin) Peritoneal Dialysis Solution; Drug
Lead sponsor: Vantive Health LLC; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 3
States / cities: Santa Clara, California • Michigan City, Indiana • Lincoln, Nebraska

Conditions: Severe Hypertriglyceridemia
Interventions: Olezarsen, Placebo; Drug
Lead sponsor: Ionis Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 446 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 63
States / cities: Birmingham, Alabama • Peoria, Arizona • Los Angeles, California + 51 more

Conditions: Healthy Participants
Interventions: Laroprovstat Dose X/Rosuvastatin Dose 1 FCDP test formulation 1, Laroprovstat Dose X/Rosuvastatin Dose 2 FCDP test formulation 1, Laroprovstat Dose X/Rosuvastatin Dose 1 FCDP test formulation 2, Laroprovstat Dose X/Rosuvastatin Dose 2 FCDP test formulation 2, Laroprovstat Dose X STP, Rosuvastatin Dose 1 STP, Rosuvastatin Dose 2 STP; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 44 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 2
States / cities: Glendale, California • Brooklyn, Maryland

Conditions: Hypercholesterolemia, ASCVD
Interventions: Referral to Pharmacist-Driven Medication Management Program, Best-Practice Alert; Behavioral
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years to 95 Years
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: HYPERTENSION, HYPERCHOLESTEROLEMIA
Interventions: valsartan + simvastatin; Drug
Lead sponsor: Novartis; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 369 participants
Timeline: Started 2004
U.S. locations: 1
States / cities: East Hanover, New Jersey

Conditions: Hypercholesterolemia
Interventions: Lapaquistat acetate and rosuvastatin, Rosuvastatin; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older
Enrollment: 415 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 82
States / cities: Birmingham, Alabama • Haleyville, Alabama • Mobile, Alabama + 79 more

Conditions: Heart Failure, High Blood Pressure, High Cholesterol, Anemia, Diabetes, Thyroid Diseases, Kidney Diseases, Clotting Disorder, Trauma, Other Disease
Interventions: BVA-200; Diagnostic Test
Lead sponsor: Daxor Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 62 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Oak Ridge, Tennessee

Conditions: Metabolic Syndrome, Hypertriglyceridemia
Interventions: omega-3 acid ethyl esters, extended release niacin, placebo, combined treatment; Drug
Lead sponsor: University of South Dakota; Other
Eligibility: 40 Years to 69 Years
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Sioux Falls, South Dakota

Conditions: Hypertriglyceridemia
Interventions: DHA-O, Fish oil, Placebo; Dietary Supplement
Lead sponsor: dsm-firmenich Switzerland AG; Industry
Eligibility: 18 Years to 79 Years
Enrollment: 93 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Addison, Illinois

Conditions: Stroke
Interventions: Community Health Worker (CHW), usual care and health education brochures every 4 months.; Behavioral · Other
Lead sponsor: University of Miami; Other
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Familial Hypercholesterolemia
Interventions: Cascade screening; Behavioral
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older
Enrollment: 800 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Hyperlipidemia
Interventions: A: NK-104-CR 8 mg, B: Pitavastatin IR 4 mg, C: Pitavastatin IR 8 mg; Drug
Lead sponsor: Kowa Research Institute, Inc.; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Hypertriglyceridemia
Interventions: 4/day of 4g P-OM3 capsules, 4/day of 1g P-OM3 capsules, Corn Oil Placebo, 4 capsules/day for 8 weeks; Drug
Lead sponsor: Penn State University; Other
Eligibility: 21 Years to 65 Years
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: University Park, Pennsylvania

Conditions: Dyslipidemia
Interventions: Lapaquistat Acetate, Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older
Enrollment: 361 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 47
States / cities: Northport, Alabama • Mesa, Arizona • Chula Vista, California + 44 more

Conditions: Cardiovascular Disease, Hyperlipidemia
Interventions: Avocado Diet, Lower-Fat Diet, Moderate Fat Diet; Other
Lead sponsor: Penn State University; Other
Eligibility: 21 Years to 70 Years
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: University Park, Pennsylvania

Conditions: Hypercholesterolemia, Hypertension, Depression, Diabetes Mellitus, Type 2
Interventions: Health at Every Size (HAES), Diet (Traditional, moderate energy restriction); Behavioral
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 30 Years to 45 Years · Female only
Enrollment: 79 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2000
U.S. locations: 2
States / cities: Davis, California

Conditions: Hypercholesterolemia, Coronary Heart Disease
Interventions: Ezetimibe, Phytosterols + ezetimibe, Placebo; Drug · Other
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years to 80 Years
Enrollment: 22 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Logan, Utah

Conditions: Inflammation, Metabolic Disorder, Hypertriglyceridemia
Interventions: Aronia juice, Placebo; Dietary Supplement · Other
Lead sponsor: Montana State University; Other
Eligibility: 18 Years to 60 Years
Enrollment: 13 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Bozeman, Montana

Conditions: HIV Infections, AIDS, Dyslipidemia, Hypertriglyceridemia
Interventions: Omega-3 fatty acid administration, Placebo; Drug
Lead sponsor: Brown, Todd, M.D., Ph.D.; Individual
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 3
States / cities: Los Angeles, California • Washington D.C., District of Columbia • Baltimore, Maryland

Conditions: Hypercholesterolemia
Interventions: atorvastatin; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 25 Years and older
Enrollment: 260 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: HIV Infection, Hyperlipidemia
Interventions: Atazanavir, current antiretroviral regimen; Drug
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 5
States / cities: San Diego, California • Chicago, Illinois • Indianapolis, Indiana + 2 more

Conditions: Hypercholesterolemia, Mixed Dyslipidemia, Type 2 Diabetes
Interventions: Evolocumab, Placebo to Evolocumab; Biological · Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years and older
Enrollment: 424 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 46
States / cities: Tuscumbia, Alabama • Phoenix, Arizona • Lomita, California + 39 more

Search by objective public record fields.

The Effect of Synching Prescription Refills on Adherence

MEDication Focused Outpatient Care for Underutilization of Secondary Prevention

Effect of Extraneal (Icodextrin)on Triglyceride Levels in PD Patients

A Study of Olezarsen Administered Subcutaneously to Participants With Severe Hypertriglyceridemia

A Phase I Study Comparing the Relative Bioavailability of a Fixed-Dose Combination of Laroprovstat/Rosuvastatin vs Their Single Therapy Products in Healthy Adults

Improving Lipid Optimization Quality and Treatment Options in ASCVD

A 10-12 Week Study to Evaluate the Safety and Efficacy of 320 mg Valsartan and 80 mg Simvastatin in Combination and as Monotherapies in Treating Hypertension and Hypercholesterolemia

Efficacy of Lapaquistat Acetate Alone or Combined With Rosuvastatin in Subjects With Hypercholesterolemia

BVA-200 vs BVA-100 Validation Study

Niacin, N-3 Fatty Acids and Insulin Resistance

Efficacy and Safety Study of DHA-O in Adults With Hypertriglyceridemia

Hispanic Secondary Stroke Prevention Initiative

Penn Family Screening for Familial Hypercholesterolemia

A Comparison Study to Evaluate the Pharmacokinetics and Safety of NK-104-CR in Healthy Adult Volunteers

Vascular and Lipid Effects of Omega-3 Fatty Acids in People With Moderately Elevated Triglycerides

Effect of Lapaquistat Acetate on Blood Cholesterol Levels in Subjects With Elevated Cholesterol

The Effect of Avocado on Cardiovascular Disease (CVD) Risk Factors

Evaluating "Health at Every Size"(HAES) as an Alternative Obesity Treatment Model

Phytosterols, Ezetimibe, and Cholesterol Metabolism

Impact of Aronia Berry Consumption on Inflammation, Metabolites, and the Gut Microbiome

Omega-3 Fatty Acids for High Triglycerides in HIV-infected Patients

Statin Interchange by Pharmacist Collaborative Practice Agreement (CPA)

Switch to Atazanavir and Brachial Artery Reactivity (SABAR) Study

Evaluation of Evolocumab (AMG 145) Efficacy in Diabetic Adults With Hypercholesterolemia/Mixed Dyslipidemia